User login
Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).
Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.
Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).
Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.
Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681
Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).
Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.
Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).
Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.
Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681
Key clinical point: Findings from this real-world study supported the previous evidence for improved clinical outcomes on adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy (TCT) in patients with human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (BC).
Major finding: The pathological complete response (odds ratio 1.74; P = .032) and 5-year event-free survival (hazard ratio, 2.22; P = .041) rates were significantly worsened in patients receiving TCT vs pertuzumab+TCT. The incidence of serious adverse events did not differ significantly between both groups.
Study details: Findings are from a retrospective, observational study including 271 patients with HER2+ stage II-III BC who received TCT with (n = 137) or without pertuzumab (n = 134).
Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.
Source: Fabbri A et al. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: The Neopearl nationwide collaborative study. Front Oncol. 2023;13:1177681 (Jun 27). Doi: 10.3389/fonc.2023.1177681